TY - JOUR
T1 - Recent advances in radiation oncology
T2 - Intensity-modulated radiotherapy, a clinical perspective
AU - Nakamura, Katsumasa
AU - Sasaki, Tomonari
AU - Saiji, Ohga
AU - Yoshitake, Tadamasa
AU - Terashima, Kotaro
AU - Asai, Kaori
AU - Matsumoto, Keiji
AU - Shioyama, Yoshiyuki
AU - Honda, Hiroshi
N1 - Funding Information:
This study was supported in part by KAKENHI (No. 26670563) and a Health Labor Sciences Research Grant (H23-Sanjigan-Ippan-007) from the Japanese Ministry of Health, Labor and Welfare.
PY - 2014/8
Y1 - 2014/8
N2 - Radiotherapy plays an important role in the treatment of various malignancies, and intensity-modulated radiotherapy (IMRT) is an attractive option because it can deliver precise conformal radiation doses to the target while minimizing the dose to adjacent normal tissues. IMRT provides a highly conformal dose distribution by modulating the intensity of the radiation beam. A number of malignancies have been targeted by IMRT; this work reviews published data on the major disease sites treated with IMRT. The dosimetric advantage of IMRT has resulted in the significant reduction of adverse effects in some tumors. However, there are few clinical trials comparing IMRT and three-dimensional conformal radiotherapy (3D-CRT), and no definite increase in survival or the loco-regional control rate by IMRT has been demonstrated in many malignancies. IMRT also requires greater time and resources to complete compared to 3D-CRT. In addition, the cost-effectiveness of IMRT versus 3D-CRT has not yet been established.
AB - Radiotherapy plays an important role in the treatment of various malignancies, and intensity-modulated radiotherapy (IMRT) is an attractive option because it can deliver precise conformal radiation doses to the target while minimizing the dose to adjacent normal tissues. IMRT provides a highly conformal dose distribution by modulating the intensity of the radiation beam. A number of malignancies have been targeted by IMRT; this work reviews published data on the major disease sites treated with IMRT. The dosimetric advantage of IMRT has resulted in the significant reduction of adverse effects in some tumors. However, there are few clinical trials comparing IMRT and three-dimensional conformal radiotherapy (3D-CRT), and no definite increase in survival or the loco-regional control rate by IMRT has been demonstrated in many malignancies. IMRT also requires greater time and resources to complete compared to 3D-CRT. In addition, the cost-effectiveness of IMRT versus 3D-CRT has not yet been established.
UR - http://www.scopus.com/inward/record.url?scp=84906350952&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84906350952&partnerID=8YFLogxK
U2 - 10.1007/s10147-014-0718-y
DO - 10.1007/s10147-014-0718-y
M3 - Review article
C2 - 24981775
AN - SCOPUS:84906350952
SN - 1341-9625
VL - 19
SP - 564
EP - 569
JO - International Journal of Clinical Oncology
JF - International Journal of Clinical Oncology
IS - 4
ER -